The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1684
ISSUE 1684
September 4, 2023
Issue 1684
- Drugs for Opioid Use Disorder
- Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
- Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
- In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)
- Talquetamab (Talvey) for Multiple Myeloma (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Opioid Use Disorder
September 4, 2023 (Issue: 1684)
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis,...more
- NIH. Drug overdose death rates. June 30, 2023. Available at: https://bit.ly/3rQyEmF. Accessed August 17, 2023.
- American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med 2020; 14(2S Suppl 1):1. doi:10.1097/adm.0000000000000633
- Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. Version 4.0 – 2021. Available at: https://bit.ly/3CkSSEp. Accessed August 17, 2023.
- Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) series 63 publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021. Available at: https://bit.ly/3Yh7UYr. Accessed August 17, 2023.
- Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. 2018. Available at: https://bit.ly/43X3GXf. Accessed August 17, 2023.
- Institute for Safe Medication Practices. Keeping patients safe from iatrogenic methadone overdoses. February 14, 2008. Available at: https://bit.ly/458otIl. Accessed August 17, 2023.
- Substance Abuse and Mental Health Services Administration. Emerging issues in the use of methadone. HHS publication No. (SMA) 09-4368. Substance abuse treatment advisory 2009. Available at: https://bit.ly/3QIgbD5. Accessed August 17, 2023.
- RP Mattick et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3:CD002209. doi:10.1002/14651858.cd002209.pub2
- F Faggiano et al. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3:CD002208. doi:10.1002/14651858.cd002208
- L Gowing et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; 8:CD004145. doi:10.1002/14651858.cd004145.pub4
- S Nolan et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014; 109:2053. doi:10.1111/add.12682
- T Santo Jr. et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry 2021; 78:979. doi:10.1001/jamapsychiatry.2021.0976
- L Lappalainen et al. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction 2015; 110:1330. doi:10.1111/add.12970
- L Sordo et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357:j1550. doi:10.1136/bmj.j1550
- RL Woosley et al. QTdrugs list. Available at: www.crediblemeds.org. Accessed August 17, 2023.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- U.S. Government Publishing Office. 42 CFR 8.12 – Federal opioid treatment standards. October 1, 2002. Available at: https://bit.ly/45nY8Xz. Accessed August 17, 2023.
- LE Baxter Sr et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med 2013; 7:377. doi:10.1097/01.adm.0000435321.39251.d7
- Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.
- In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther 2013; 55:83.
- Bunavail: another buprenorphine/naloxone formulation for opioid dependence. Med Lett Drugs Ther 2015; 57:19.
- Once-weekly or once-monthly subcutaneous buprenorphine (Brixadi) for opioid use disorder. Med Lett Drugs Ther 2023; 65:133.
- Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. Med Lett Drugs Ther 2018; 60:35.
- Substance Abuse and Mental Health Services Administration. Waiver elimination (MAT Act). June 7, 2023. Available at: https://bit.ly/3Q7YpZT. Accessed August 17, 2023.
- TV Parran et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106:56. doi:10.1016/j.drugalcdep.2009.07.013
- DP Kao et al. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction 2015; 110:1468. doi:10.1111/add.13013
- L Kohan et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med 2021; 46:840. doi:10.1136/rapm-2021-103007
- DR Wesson and W Ling. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253. doi:10 .1080/02791072.2003.10400007
- S Ahmed et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict 2021; 30:305. doi:10.1111/ajad.13135
- MK Greenwald et al. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med 2022; 80:509. doi:10.1016/j.annemergmed.2022.05.032
- Naltrexone (Vivitrol) – a once-monthly injection for alcoholism. Med Lett Drugs Ther 2006; 48:62.
- JD Lee et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med 2016; 374:1232. doi:10.1056/nejmoa1505409
- E Krupitsky et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377:1506. doi:10.1016/s0140-6736(11)60358-9
- JD Lee et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309. doi:10.1016/s0140-6736(17)32812-x
- L Tanum et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry 2017; 74:1197. doi:10.1001/jamapsychiatry.2017.3206
- J Ma et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry 2019; 24:1868. doi:10.1038/s41380-018-0094-5
- S Minozzi et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; 4:CD001333. doi:10.1002/14651858.cd001333.pub4
- Y Adi et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007; 11:iii. doi:10.3310/hta11060
- SD Comer et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159:351. doi:10.1007/s002130100909
- M Ferri et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev 2013; 6:CD009879. doi:10.1002/14651858.cd009879.pub2
- J Klimas et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open 2019; 9:e025799. doi:10.1136/bmjopen-2018-025799
- M Ferri et al. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2011; 12:CD003410. doi:10.1002/14651858.cd003410.pub4
- S-Y Lee et al. A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment. Int J Neuropsychopharmacol 2015; 18:pyv008. doi:10.1093/ijnp/pyv008
- DA Fiellin et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013; 126:74. doi:10.1016/j.amjmed.2012.07.005
- Substance Abuse and Mental Health Services Administration. Evidence-based, whole-person care for pregnant people who have opioid use disorder. May 2023. Available at: https://bit.ly/4455IVk. Accessed August 17, 2023.
- HE Jones et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320. doi:10.1056/nejmoa1005359
- SL Wiegand et al. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015; 125:363. doi:10.1097/aog.0000000000000640
- Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Naltrexone. Updated 2022 September 19. Available at: https://bit.ly/3OMJcw5. Accessed August 17, 2023.
- Zimhi – a higher-dose injectable naloxone for opioid overdose. Med Lett Drugs Ther 2022; 64:61.
- In brief: Higher-dose naloxone nasal spray (Kloxxado) for opioid overdose. Med Lett Drugs Ther 2021; 63:151.
- Naloxone (Narcan) nasal spray for opioid overdose. Med Lett Drugs Ther 2016; 58:1.
- Legislative Analysis and Public Policy Association. Naloxone: summary of state laws. February 3, 2023. Available at: https://bit.ly/3Kxgw7N. Accessed August 17, 2023.
- HHS. Naloxone: the opioid reversal drug that saves lives. Available at: https://bit.ly/3k68NiV. Accessed August 17, 2023.
- In brief: Over-the-counter Narcan nasal spray. Med Lett Drugs Ther 2023; 65:72.
- In brief: A new OTC naloxone nasal spray (RiVive). Med Lett Drugs Ther 2023 (in press).
- EW Boyer. Management of opioid analgesic overdose. N Engl J Med 2012; 367:146. doi:10.1056/nejmra1202561
- Nalmefene nasal spray (Opvee) for reversal of opioid overdose. Med Lett Drugs Ther 2023 (in press).
- Nalmefene returns for reversal of opioid overdose. Med Lett Drugs Ther 2022; 64:141.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1684
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.